VIDEO: Melphalan dosing, immunotherapy considered in multiple myeloma research
Click Here to Manage Email Alerts
NEW ORLEANS — In this video perspective, Rahul Banerjee, MD, FACP, discusses potentially practice-changing early research on treatments for newly diagnosed multiple myeloma presented at the ASH Annual Meeting and Exposition.
Banerjee, an assistant professor at the University of Washington, highlights two studies, including one prospective randomized trial of long-term outcomes of treatment with continuous lenalidomide/dexamethasone vs. MEL140 with autologous blood stem cell transplantation and one phase 1 study of GC012F chimeric antigen receptor T-cell therapy as potential first-line therapy in transplant eligible patients with high-risk multiple myeloma.
Results in the MEL140 study were negative, Banerjee said.
“In this particular case, the use of melphalan 140 mg/m2, which we often do for patients who are frailer, on dialysis ... did not improve outcomes at all” against the comparator, he said.
Whereas the study of GC012F immunotherapy, which is still in early phase, could be practice changing someday, Banerjee said, in that patients receiving the treatment had a 100% response rate at all dose levels.
References:
- Straka C, et al. Abstract 116. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
- Du J, et al. Abstract 366. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.
Collapse
Healio Interviews
Click Here to Manage Email Alerts